Maintenance strategies after anti-EGFR-based induction in metastatic colorectal cancer: A systematic review and bayesian network meta-analysis

Cancer statistics, 2022

(2022) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO

(2022) Daniele Rossini et al.   JOURNAL OF CLINICAL ONCOLOGY

Negative hyperselection for mutations associated with anti-EGFR antibody resistance in RAS wildtype metastatic colorectal cancer (mCRC): Evaluation of the PANAMA trial (AIO-KRK-0212, maintenance therapy with 5-FU, folinic acid (FU/FA) with or without panitumumab).

(2022) Andreas Jay Kind et al.   JOURNAL OF CLINICAL ONCOLOGY

Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Results from the phase 3 PARADIGM trial.

(2022) Takayuki Yoshino et al.   JOURNAL OF CLINICAL ONCOLOGY

Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†

(2022) A. Cervantes et al.   ANNALS OF ONCOLOGY

Treatment of Metastatic Colorectal Cancer: ASCO Guideline

(2022) Van K. Morris et al.   JOURNAL OF CLINICAL ONCOLOGY

Maintenance treatment with cetuximab versus observation in RAS wild-type metastatic colorectal cancer: Results of the randomized phase II PRODIGE 28-time UNICANCER study.

(2021) Valerie Boige et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: A meta-analysis of individual patients’ data from 3 phase III studies

(2021) Lisa Salvatore et al.   CANCER TREATMENT REVIEWS

Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212)

(2021) Dominik Paul Modest et al.   JOURNAL OF CLINICAL ONCOLOGY

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

(2020) Chiara Cremolini et al.   LANCET ONCOLOGY

Effect of Reduced-Dose Capecitabine Plus Cetuximab as Maintenance Therapy for RAS Wild-Type Metastatic Colorectal Cancer

(2020) Lu Wang et al.   JAMA Network Open

Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: a retrospective analysis of two randomised trials

(2019) Dominik Paul Modest et al.   INTERNATIONAL JOURNAL OF CANCER

Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years

(2019) Fanny ER Vuik et al.   GUT

Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer

(2019) Filippo Pietrantonio et al.   JAMA Oncology

SAPPHIRE: a randomised phase II study of planned discontinuation or continuous treatment of oxaliplatin after six cycles of modified FOLFOX6 plus panitumumab in patients with colorectal cancer

(2019) Y. Munemoto et al.   EUROPEAN JOURNAL OF CANCER

Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy

(2019) Federica Morano et al.   JOURNAL OF CLINICAL ONCOLOGY

The Role of Maintenance Strategies in Metastatic Colorectal Cancer

(2019) Mohamad Bassam Sonbol et al.   JAMA Oncology

Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer

(2018) Chiara Cremolini et al.   JAMA Oncology

First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study

(2018) E. Aranda et al.   EUROPEAN JOURNAL OF CANCER

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial

(2016) Sebastian Stintzing et al.   LANCET ONCOLOGY

Impact of early tumour shrinkage and resection on outcomes in patients with wild-type RAS metastatic colorectal cancer

(2015) Jean-Yves Douillard et al.   EUROPEAN JOURNAL OF CANCER

Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment andRASMutations in Colorectal Cancer

(2015) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer

(2014) J. Y. Douillard et al.   ANNALS OF ONCOLOGY

Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial

(2014) Harpreet Wasan et al.   LANCET ONCOLOGY

Use of Early Tumor Shrinkage to Predict Long-Term Outcome in Metastatic Colorectal Cancer Treated With Cetuximab

(2013) Hubert Piessevaux et al.   JOURNAL OF CLINICAL ONCOLOGY

The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy

(2011) C. Suzuki et al.   ANNALS OF ONCOLOGY

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

(2009) Eric Van Cutsem et al.   NEW ENGLAND JOURNAL OF MEDICINE